217 related articles for article (PubMed ID: 22054231)
41. Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.
Kong L; Tang Y; Zhang X; Lu G; Yu M; Shi Q; Wu X
Ann Pharmacother; 2017 Nov; 51(11):970-975. PubMed ID: 28677407
[TBL] [Abstract][Full Text] [Related]
42. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
Xiao YH; Hu YJ
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
[No Abstract] [Full Text] [Related]
43. Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study.
Zhao HY; Gu J; Lyu J; Liu D; Wang YT; Liu F; Zhu FX; An YZ
Chin Med J (Engl); 2017 May; 130(10):1139-1145. PubMed ID: 28485312
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study.
Braune S; König C; Roberts JA; Nierhaus A; Steinmetz O; Baehr M; Kluge S; Langebrake C
Crit Care; 2018 Jan; 22(1):25. PubMed ID: 29382394
[TBL] [Abstract][Full Text] [Related]
45. Population Pharmacokinetics/Pharmacodynamics and Clinical Outcomes of Meropenem in Critically Ill Patients.
Boonpeng A; Jaruratanasirikul S; Jullangkoon M; Samaeng M; Wattanavijitkul T; Bhurayanontachai R; Pattharachayakul S
Antimicrob Agents Chemother; 2022 Nov; 66(11):e0084522. PubMed ID: 36226944
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetic–pharmacodynamic target attainment analysis of meropenem in Japanese adult patients.
Ikawa K; Morikawa N; Ohge H; Ikeda K; Sueda T; Taniwaki M; Kurisu K
J Infect Chemother; 2010 Feb; 16(1):25-32. PubMed ID: 20082106
[TBL] [Abstract][Full Text] [Related]
47. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Moczygemba LR; Frei CR; Burgess DS
Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
[TBL] [Abstract][Full Text] [Related]
48. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Sun HK; Kuti JL; Nicolau DP
Crit Care Med; 2005 Oct; 33(10):2222-7. PubMed ID: 16215374
[TBL] [Abstract][Full Text] [Related]
49. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
[TBL] [Abstract][Full Text] [Related]
50. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients.
Du X; Li C; Kuti JL; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2006 Jan; 46(1):69-75. PubMed ID: 16397286
[TBL] [Abstract][Full Text] [Related]
51. A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients.
Mathew SK; Mathew BS; Neely MN; Naik GS; Prabha R; Jacob GG; K S; Fleming DH
Ther Drug Monit; 2016 Oct; 38(5):593-9. PubMed ID: 27454665
[TBL] [Abstract][Full Text] [Related]
52. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate.
Bradley JS; Sauberan JB; Ambrose PG; Bhavnani SM; Rasmussen MR; Capparelli EV
Pediatr Infect Dis J; 2008 Sep; 27(9):794-9. PubMed ID: 18645546
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics of continuous-infusion meropenem for the treatment of Serratia marcescens ventriculitis in a pediatric patient.
Cies JJ; Moore WS; Calaman S; Brown M; Narayan P; Parker J; Chopra A
Pharmacotherapy; 2015 Apr; 35(4):e32-6. PubMed ID: 25884534
[TBL] [Abstract][Full Text] [Related]
54. Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.
Cojutti P; Sartor A; Righi E; Scarparo C; Bassetti M; Pea F
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760900
[TBL] [Abstract][Full Text] [Related]
55. Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles.
Nicolau DP
Infection; 2001 Dec; 29 Suppl 2():11-5. PubMed ID: 11785851
[TBL] [Abstract][Full Text] [Related]
56. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy.
Highet VS; Forrest A; Ballow CH; Schentag JJ
J Antimicrob Chemother; 1999 Mar; 43 Suppl A():55-63. PubMed ID: 10225573
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit.
Xu Y; Jin L; Liu N; Luo X; Dong D; Tang J; Wang Y; You Y; Liu Y; Chen M; Yu Z; Hao Y; Gu Q
Int J Infect Dis; 2019 May; 82():79-85. PubMed ID: 30878630
[TBL] [Abstract][Full Text] [Related]
58. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
O'Jeanson A; Larcher R; Le Souder C; Djebli N; Khier S
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):695-705. PubMed ID: 34403127
[TBL] [Abstract][Full Text] [Related]
59. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
Kuti JL; Florea NR; Nightingale CH; Nicolau DP
Pharmacotherapy; 2004 Jan; 24(1):8-15. PubMed ID: 14740783
[TBL] [Abstract][Full Text] [Related]
60. Comparison of Short Versus Prolonged Infusion of Standard Dose of Meropenem Against Carbapenemase-Producing Klebsiella pneumoniae Isolates in Different Patient Groups: A Pharmacokinetic-Pharmacodynamic Approach.
Vourli S; Tsala M; Kotsakis S; Daikos GL; Tzouvelekis L; Miriagou V; Zerva L; Meletiadis J
J Pharm Sci; 2016 Apr; 105(4):1513-8. PubMed ID: 27019965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
